Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

por Hallqvist, A., Enlund, F., Andersson, C., Sjögren, H., Hussein, A., Holmberg, E., Nyman, J.
Publicado 2012